

On-line Table 1: Summary of patients and aneurysm characteristics

Sex/ Age (yr)	Vascular Risk Factors	Other Intracranial Aneurysms	Aneurysm Location	Aneurysm Size (mm) (Neck × Dome × Height)	Aneurysm Characteristics	mRS before Treatment (GCS at Presentation if Acute SAH)
1) M/59	No	No	Rt MCA bif	5 × 9 × 6	U	0
2) F/74	Hypertension + smoking	No	Basilar tip	9 × 10 × 10	U	0
3) M/64	Smoking	Yes	L MCA bif	8 × 14 × 7 (Bilobulated aneurysm)	U	0
4) F/57	Hypertension	No	Rt MCA bif	6 × 8 × 6	R (Fisher 2)	0 (GCS 14)
5) F/73	Hypertension	No	Acoma	4 × 6 × 4	U	0
6) F/61	Hypertension + smoking	No	Rt Pcoma	6 × 9 × 10	U	0
7) F/75	Smoking	No	L A1, A2	4 × 6 × 5	R (Fisher 3)	0 (GCS 8)
8) M/56	Hypertension + smoking	No	Basilar tip	9 × 9 × 7	U	0
9) F/58	No	Yes	Rt MCA bif	5 × 6 × 3	U	4
10) F/72	Smoking	No	L MCA bif	4 × 4 × 4	U	0
11) F/72	Hypertension + smoking	No	Rt MCA bif	4 × 4 × 4	U	0
12) F/39	Hypertension + smoking	Yes	Rt MCA (temporal branch)	3 × 3 × 3	U	1
13) M/60	Hypertension + smoking	No	Rt M3 (angular artery)	5 × 4 (Fusiform)	U	0
14) F/60	Hypertension + smoking	No	L MCA bif	4 × 4 × 4	U	0
15) M/62	No	No	Rt MCA (temporal branch)	2 × 3 × 3	U	0
16) F/57	Smoking	No	L A1, A2	4 × 4 × 3	U	0
17) F/60	Smoking	No	Basilar tip	7 × 11 × 8	Previously R and coiled (recanalization)	0

Note:—U indicates unruptured; R, ruptured; bif, bifurcation; Rt, right; L, left; GCS, Glasgow Coma Scale.

On-line Table 2: Summary of treatment, patient outcome, and follow-up results^a

Pt. No.	Type of WEB and Size	Type of Stent/Planned Stent	Duration of Treatment/ Time of Fluoroscopy (min)	Intra- and Peri-Procedural Complications	Long-Term Complications	Immediate Aneurysm Occlusion after Treatment	Aneurysm Occlusion during FU	Recanalization/Retreatment	Last Angiographic FU (mo)/Type of FU	Length of Clinical FU (mo)/mRS during FU
1	SL 10 × 5	NF Atlas 3 × 24/no	105/30	No	No	RR III (stagnation)	RR II	No	6/DSA	6/mRS 0
2	SL 11 × 9	NF Atlas 3 × 20/no	100/25	No	No	RR III (stagnation)	RR III	Yes (after 6 mo)/ Y-stenting + coiling	6/DSA	7/mRS 0
3	SL 9 × 6 + SL 9 × 6	Y-stenting LEO 2 × 18/yes	75/50	No	No	RR I	RR I	No	36/DSA	36/mRS 0
4	SL 9 × 5	NF Atlas 3 × 24/no	100/70	Small in-stent platelet aggregation (reversible after abciximab)	No	RR II	RR I	No	24/DSA	24/mRS 0
5	SL 7 × 3	NF Atlas 3 × 20/no	105/41	No	No	RR I	RR I	No	12/DSA	16/mRS 0
6	SL 10 × 5	PED 3.5 × 18/yes	75/28	No	No	RR I	RR I	No	12/DSA	15/mRS 0
7	SL 7 × 4	NF Atlas 3 × 24/no	100/33	Small in-stent platelet aggregation (reversible after abciximab)	No	RR I	NA	NA	NA	mRS 6
8	SL 10 × 5	NF Atlas 4 × 30/no	50/31	No	No	RR III (stagnation)	RR III	Yes (after 10 mo)/ Y-stenting + coiling	6/MRA	6/mRS 0
9	SL 7 × 3	LEO 2 × 18/yes	60/22	No	No	RR III (stagnation)	RR I	No	6/DSA	8/mRS 4
10	SL 5 × 3	NF Atlas 3 × 24/yes	80/47	No	No	RR III (stagnation)	RR I	No	6/DSA	6/mRS 0
11	SL 5 × 3	NF Atlas 4 × 24/no	100/59	No	No	RR III (stagnation)	RR I	No	6/DSA	6/mRS 0
12	SL 3 × 2	NF Atlas 4 × 15/yes	70/29	No	No	RR III (stagnation)	RR I	No	6/DSA	6/mRS 1
13	SL 6 × 3	NF Atlas 3 × 24/yes	70/29	No	Asymptomatic occlusion of angular artery during FU	RR III (stagnation)	RR I	No	12/DSA	12/mRS 0
14	SL 5 × 3	NF Atlas 3 × 24/yes	50/17	No	No	RR III (stagnation)	RR II	No	8/DSA	12/mRS 0
15	SL 4 × 2	NF Atlas 3 × 24/yes	74/38	No	No	RR I	RR I	No	8/DSA	8/mRS 0
16	SL 5 × 2	NF Atlas 3 × 21/yes	64/34	No	No	RR III	RR I	No	7/MRA	6/mRS 0
17	SL 9 × 6	Y-stenting NF Atlas 3 × 20 + 3 × 30/yes	65/18	No	No	RR I	RR III	Yes (after 3 mo)/coiling	6/DSA	6/mRS 0

Note:—Pt. indicates patient; FU, follow-up; NA, not applicable; NF, Neuroform.^a Device sizes are in millimeters.